^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AVA6000

    i
    Other names: AVA6000, FAP-activated doxorubicin prodrug
    Associations

    News

    Trials
    Company:
    Avacta
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    ALS-6000-101: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours (clinicaltrials.gov)
    P1, N=158, Recruiting, Avacta Life Sciences Ltd | N=80 --> 158 | Trial completion date: Jun 2023 --> Aug 2026 | Trial primary completion date: May 2023 --> Mar 2026
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    doxorubicin hydrochloride • AVA6000
    almost3years
    AVA6000, a novel Precision medicine, targeted to the tumor microenvironment via Fibroblast Activation Protein (FAP) mediated cleavage (AACR 2022)
    In a PDX model of osteosarcoma, AVA6000 significantly decreased tumor volume while doxorubicin had no significant effect. The efficacy and tolerability profile of AVA6000 strongly support its clinical development, and a Phase I trial in patients with locally advanced or metastatic selected solid tumours in underway.
    FAP (Fibroblast activation protein, alpha)
    |
    AVA6000